• MCL-1 Dependence in Breast Cancer: Apoptotic Control

  2026-08-31

  This 2021 study shows that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic activity, rather than an exclusively non-apoptotic function. Genetic deletion and pharmacological inhibition both required BAX/BAK to suppress tumor growth, providing a mechanistic rationale for MCL-1-directed therapy while clarifying how mitochondrial apoptosis should be evaluated.

• Imipenem Workflows for Antibacterial Research

  2026-08-31

  Imipenem connects routine susceptibility testing with carbapenemase transmission studies, phagocyte assays, and carefully controlled sepsis animal model research. This practical guide translates PBP-directed activity into reproducible workflows, assay controls, and troubleshooting decisions.

• PPM-18 for iNOS and NF-κB Assay Design

  2026-08-30

  PPM-18 provides a chemically defined way to interrogate iNOS expression and NF-κB-dependent inflammation without directly targeting constitutive NOS enzymes. This workflow connects macrophage nitrite assays and sepsis research with the redox-sensitive atrial ANP model described in the reference study, while clearly separating established evidence from exploratory applications.

• BIBP 3226 trifluoroacetate in NPY Research

  2026-08-29

  BIBP 3226 trifluoroacetate is a practical pharmacological probe for separating NPY Y1 and NPFF-linked signaling in cAMP, neuronal, and cardiac models. This workflow-focused guide shows how to use its affinity profile to interrogate the adipose-neural axis while avoiding common interpretation, solubility, and vehicle-control errors.

• KR-12, LL-37, and Selective Biofilm Activity

  2026-08-29

  The 2017 Frontiers in Microbiology study compared LL-37 with its truncated mimetics KE-18 and KR-12 across planktonic and biofilm models of Candida albicans, Staphylococcus aureus, and Escherichia coli. Its central contribution was showing that minimum inhibitory activity and biofilm prevention are separable phenotypes, an important consideration when evaluating short host-defense peptide fragments.

• Tyrothricin: Membrane Biology Meets Organelle Transfer

  2026-08-28

  Explore Tyrothricin, a peptide antibiotic mixture, through a systems-biology lens that connects microbial membrane injury with host-cell organelle quality control. This research-focused guide translates mitochondrial-transfer findings into better assay design without overstating therapeutic or mechanistic conclusions.

• Parathyroid hormone (1-34) (human) in Cell Assays

  2026-08-28

  This scenario-driven guide explains how Parathyroid hormone (1-34) (human), SKU A1129, can improve experimental planning for receptor signaling, viability, proliferation, and bone-related assays. It connects potency benchmarks, formulation constraints, handling, and interpretation to practical laboratory decisions.

• Pretomanid Targets Terminal Oxidases in TB

  2026-08-27

  The reference study identifies simultaneous inhibition of the cytochrome bcc:aa3 and cytochrome bd terminal oxidases as a key respiratory mechanism of pretomanid, also known as PA-824. Its combination data support rational regimens pairing pretomanid with Q203 and ND-011992 to increase bactericidal activity and reduce resistance emergence in replicating and non-replicating Mycobacterium tuberculosis.

• ABT-737 for BCL-2-Driven Apoptosis Research

  2026-08-27

  ABT-737 is a practical BCL-2 protein inhibitor for connecting mitochondrial apoptosis, cancer-cell sensitivity, and BAX/BAK pore biology. This guide translates its biochemical profile into cell-treatment, imaging, and troubleshooting workflows for lymphoma, multiple myeloma, SCLC, and AML research.

• Haloprogin: What the 1970 Study Established

  2026-08-26

  The 1970 reference study established Haloprogin as a topical antifungal with dermatophyte activity comparable to tolnaftate, while also demonstrating stronger activity against yeasts and selected Gram-positive bacteria. Its combined serial-dilution, fungicidal, serum-effect, and guinea pig infection experiments remain useful for interpreting spectrum, formulation, and translational limitations.

• Coumestrol and PMAIP1-Driven Ferroptosis in RA

  2026-08-26

  The reference study identifies a TRIM3–PMAIP1 protein-stability axis through which Coumestrol promotes ferroptosis in rheumatoid arthritis fibroblast-like synoviocytes and suppresses their proliferation and inflammatory output. Its findings provide a mechanistic framework for studying ferroptosis in RA-FLS while highlighting the need to distinguish this pathway from Coumestrol’s established nuclear receptor activities.

• Omeprazole A2845: Research Protocol Guide

  2026-08-25

  Omeprazole (SKU A2845) is a research-use H+,K+-ATPase inhibitor for controlled gastric acid secretion research and antiulcer activity study design. This guide covers DMSO stock preparation, assay controls, storage, and interpretation limits; it is not a diagnostic, clinical, or medical-use protocol.

• Angiotensin II A1042: Practical Research Guide

  2026-08-25

  Angiotensin II (A1042) provides a defined octapeptide stimulus for receptor-binding assays, vascular smooth muscle cell hypertrophy research, hypertension mechanism study, and vascular remodeling models. It is intended for controlled scientific workflows only, not for diagnostic, therapeutic, or medical use, and the listed conditions should be treated as starting points rather than universal protocols.

• Aclacinomycin A: Mechanism, Evidence & Workflows

  2026-08-24

  Aclacinomycin A, also called Aclarubicin, is an anthracycline research compound that inhibits topoisomerase I and II and promotes cancer-cell death. Product-reported in vitro IC50 values are 0.27 μM for A549, 0.32 μM for HepG2, and 0.62 μM for MCF-7 cells, although the source record does not specify exposure duration or assay conditions.

• 2-Hydroxypropyl-β-cyclodextrin Protocol

  2026-08-23

  2-Hydroxypropyl-β-cyclodextrin is a water-compatible cyclic oligosaccharide solubilizer for screening poorly water-soluble hydrophobic compounds, especially analytes containing aromatic or phenyl groups. It is appropriate for formulation and biochemical solubility workflows, but the dossier does not establish compound-specific bioavailability, pharmacokinetics, toxicity, or therapeutic performance.

450 records 6/30 page Previous Next First page 上5页 678910 下5页 Last page